351 related articles for article (PubMed ID: 28027825)
1. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K; Leonardi C; Langley RG; Warren RB; Bachelez H; Romiti R; Ohtsuki M; Xu W; Acharya N; Solotkin K; Colombel JF; Hardin DS
J Am Acad Dermatol; 2017 Mar; 76(3):441-448.e2. PubMed ID: 28027825
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
3. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Hohenberger M; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):13-18. PubMed ID: 28521565
[TBL] [Abstract][Full Text] [Related]
5. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
6. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
[TBL] [Abstract][Full Text] [Related]
7. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
8. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry.
Shapiro JM; Zoega H; Shah SA; Bright RM; Mallette M; Moniz H; Grabert SA; Bancroft B; Merrick M; Flowers NT; Samad Z; Lidofsky S; LeLeiko NS; Sands BE
Inflamm Bowel Dis; 2016 Jun; 22(6):1456-61. PubMed ID: 26926039
[TBL] [Abstract][Full Text] [Related]
10. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data.
Etminan M; Bird ST; Delaney JA; Bressler B; Brophy JM
JAMA Dermatol; 2013 Feb; 149(2):216-20. PubMed ID: 23426479
[TBL] [Abstract][Full Text] [Related]
11. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
[TBL] [Abstract][Full Text] [Related]
12. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
13. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].
Pagenault M; Tron I; Alexandre JL; Cruchant E; Dabadie A; Chaperon J; Robaszkiewicz M; Bretagne JF
Gastroenterol Clin Biol; 1997; 21(6-7):483-90. PubMed ID: 9295976
[TBL] [Abstract][Full Text] [Related]
14. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
[TBL] [Abstract][Full Text] [Related]
15. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.
McAuliffe ME; Lanes S; Leach T; Parikh A; Faich G; Porter J; Holick C; Esposito D; Zhao Y; Fox I
Curr Med Res Opin; 2015; 31(9):1655-64. PubMed ID: 26135040
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Langley RG; Kimball AB; Nak H; Xu W; Pangallo B; Osuntokun OO; Agada N; Reich K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):333-339. PubMed ID: 30198588
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients.
Simian D; Fluxá D; Flores L; Lubascher J; Ibáñez P; Figueroa C; Kronberg U; Acuña R; Moreno M; Quera R
World J Gastroenterol; 2016 Jun; 22(22):5267-75. PubMed ID: 27298570
[TBL] [Abstract][Full Text] [Related]
20. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study.
Biancone L; Zuzzi S; Ranieri M; Petruzziello C; Calabrese E; Onali S; Ascolani M; Zorzi F; Condino G; Iacobelli S; Pallone F
J Crohns Colitis; 2012 Jun; 6(5):578-87. PubMed ID: 22398047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]